Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
132M
-
Number of holders
-
301
-
Total 13F shares, excl. options
-
105M
-
Shares change
-
-2.18M
-
Total reported value, excl. options
-
$12.1B
-
Value change
-
-$227M
-
Put/Call ratio
-
0.86
-
Number of buys
-
149
-
Number of sells
-
-121
-
Price
-
$115.17
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) as of Q4 2019
371 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK as of Q4 2019.
ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 301 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 105M shares
of 132M outstanding shares and own 79.93% of the company stock.
Largest 10 shareholders include FMR LLC (16.7M shares), WELLINGTON MANAGEMENT GROUP LLP (14.3M shares), VANGUARD GROUP INC (10.3M shares), BAILLIE GIFFORD & CO (8.19M shares), BlackRock Inc. (8.03M shares), PRICE T ROWE ASSOCIATES INC /MD/ (5.35M shares), Dodge & Cox (5.25M shares), STATE STREET CORP (2.9M shares), MAVERICK CAPITAL LTD (2.26M shares), and Bellevue Group AG (1.86M shares).
This table shows the top 301 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.